Literature DB >> 14752096

AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues.

Yuko Yamaguchi1, Mineo Kurokawa, Yoichi Imai, Koji Izutsu, Takashi Asai, Motoshi Ichikawa, Go Yamamoto, Eriko Nitta, Tetsuya Yamagata, Kazuki Sasaki, Kinuko Mitani, Seishi Ogawa, Shigeru Chiba, Hisamaru Hirai.   

Abstract

AML1 (RUNX1) is one of the most frequently disrupted genes in human leukemias. AML1 encodes transcription factors, which play a pivotal role in hematopoietic differentiation, and their inappropriate expression is associated with leukemic transformation of hematopoietic cells. Previous studies demonstrated that the transcription cofactor p300 binds to the C-terminal region of AML1 and stimulates AML1-dependent transcription during myeloid cell differentiation. Here, we report that AML1 is specifically acetylated by p300 in vitro. Mutagenesis analyses reveal that p300 acetylates AML1 at the two conserved lysine residues (Lys-24 and Lys-43). AML1 is subject to acetylation at the same sites in vivo, and p300-mediated acetylation significantly augments the DNA binding activity of AML1. Disruption of these two lysines severely impairs DNA binding of AML1 and reduced the transcriptional activity and the transforming potential of AML1. Taken together, these data indicate that acetylation of AML1 through p300 is a critical manner of posttranslational modification and identify a novel mechanism for regulating the function of AML1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14752096     DOI: 10.1074/jbc.M400355200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Developmental relationship between hematopoietic and endothelial cells.

Authors:  Jesse J Lugus; Changwon Park; Kyunghee Choi
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

Review 3.  AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors:  Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal:  Front Med       Date:  2012-08-09       Impact factor: 4.592

Review 4.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

5.  ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.

Authors:  Vanessa Paiva Leite de Sousa; Claudia Bessa Pereira Chaves; Janina Ferreira Loureiro Huguenin; Fábio Carvalho de Barros Moreira; Bruno Souza Bianchi de Reis; Leila Chimelli; Anke Bergmann; Tatiana de Almeida Simão; Luis Felipe Ribeiro Pinto
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

6.  The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.

Authors:  Lan Wang; Alexander Gural; Xiao-Jian Sun; Xinyang Zhao; Fabiana Perna; Gang Huang; Megan A Hatlen; Ly Vu; Fan Liu; Haiming Xu; Takashi Asai; Hao Xu; Tony Deblasio; Silvia Menendez; Francesca Voza; Yanwen Jiang; Philip A Cole; Jinsong Zhang; Ari Melnick; Robert G Roeder; Stephen D Nimer
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

7.  Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation.

Authors:  Dan Wu; Toshinori Ozaki; Yukari Yoshihara; Natsumi Kubo; Akira Nakagawara
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

8.  The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3.

Authors:  Luke F Peterson; Anita Boyapati; Velvizhi Ranganathan; Atsushi Iwama; Daniel G Tenen; Schickwann Tsai; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

Review 9.  AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis.

Authors:  Mineo Kurokawa
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

Review 10.  Post-translational modifications of Runx1 regulate its activity in the cell.

Authors:  Lan Wang; Gang Huang; Xinyang Zhao; Megan A Hatlen; Ly Vu; Fan Liu; Stephen D Nimer
Journal:  Blood Cells Mol Dis       Date:  2009-04-21       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.